52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial
R.G. Josse, S.R. Majumdar, Y. Zheng, J.B. Buse, J.B. Green, K.D. Kaufman, E.D. Peterson, R.R.Holman, P.W. Armstrong, on behalf of the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S372 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Impact of sitagliptin on cardiovascular and safety-related outcomes in insulin-treated type 2 diabetes: the TECOS experience
M.A. Bethel, S.S. Engel, J. Ding, R.G. Josse, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S369 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabete, Munich Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
S.S. Engel, S. Suryawanshi, R.G. Josse, E.D. Peterson, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S361 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Stimulatory effects of the long - acting kisspeptin analogue TAK - 448 on serum testosterone in men with type 2 diabetes and hypogonadotropic hypogonadism
J.T. George, J.E. Milton, A.E. Cooper, S. Greentree, R.A. Anderson and R.R. Holman
Diabetologia 2016;59:Suppl 1:S228-S229 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Estimated 10-year benefit for diabetes complication rates by 1% HbA1c decrements in people with type 2 diabetes and cardiovascular disease
S.A. Mostafa, R.R. Holman, R.L. Coleman, O. Agbaje, M.A. Bethel
Diabetologia 2016;59:Suppl 1:S543 [Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
J.B. Green, J. Alfredsson, S.R. Stevens, S.D. Reed, D.K. McGuire, P.W. Armstrong, S.S. Engel, M.A. Bethel, F. Van de Werf, E.D. Peterson, R.R. Holman
Diabetologia 2016;59:Suppl 1:S544 [Abstract]
American Heart Association (AHA) Scientific Sessions 2016, New Orleans Treated Systolic Blood Pressure and Cardiovascular Risk in Adults With Hypertension and Type 2 Diabetes: Results From the TECOS Trial
Ann M Navar, Dianne S Gallup, Yuliya Lokhnygina, Jennifer B Green, Darren K McGuire, Paul W Armstrong, John B Buse, Samuel S Engel, John M Lachin, Eberhard Standl, Frans Van de Werf, Rury R Holman, and Eric D Peterson
Circulation 2016;134:Suppl 1: [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Stratification using gender and body mass index (BMI) results in better glycaemic control for longer: a MASTERMIND study
B Shields, J Dennis, L Rodgers, A Jones, M Lonergan, W Henley, R Holman, E Pearson, A Hattersley, and the MASTERMIND Consortium
Diabetic Medicine 2016;33:Suppl 1:10-11 [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin
MA Bethel, SS Engel, JB Green, Z Huang, KD Kaufman,E Standl, S Suryawanshi, F Van de Werf, ED Peterson, and RR Holman
Diabetic Medicine 2016;33:Suppl 1:86 [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Personalisation of treatment with metformin by age, weight and sex: a MASTERMIND study
ME Lonergan, B Shields, OF Agbaje, J Dennis, M Weeden, L Rodgers, RR Holman, A Hattersley and EW Pearson
Diabetic Medicine 2016;33:Suppl 1:194 [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Baseline Characteristics of Patients Enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
ROBERT MENTZ, M ANGELYN BETHEL, STEPHANIE GUSTAVSON, VIVIAN THOMPSON, JOHN B BUSE, JULIANA CHAN, ALDO P MAGGIONI, STEVEN P MARSO, PETER OHMAN, NEIL POULTER, AMBADY RAMACHANDRAN, BERNARD ZINMAN, NAYYAR IQBAL, ADRIAN F HERNANDEZ, RURY R HOLMAN
Diabetes 2016;65:(Suppl 1):1039-P [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Assessing the Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SAMUEL S ENGEL, SHAILAJA SURYAWANSHI, ROBERT G JOSSE, ERIC PETERSON, RURY R HOLMAN, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):1181-P [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Personalizing Therapy in Type 2 Diabetes: The Effect of BMI and Gender on Response and Side Effects to Sulfonylureas and Thiazolidinediones Itinerary
JOHN M DENNIS, WILLIAM E HENLEY, MICHAEL N WEEDON, MICHAEL LONERGAN, LAUREN R RODGERS, ANGUS G JONES, RURY R HOLMAN, EWAN R PEARSON, ANDREW T HATTERSLEY, BEVERLEY M SHIELDS
Diabetes 2016;65:(Suppl 1):1541-P [Abstract]
American Diabetes Association (ADA) Conference, New Orleans Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial
ROBERT G JOSSE, SUMIT R MAJUMDAR, JOHN B BUSE, JENNIFER B GREEN, KEITH D KAUFMAN, CYNTHIA M WESTERHOUT, YINGGAN ZHENG, ERIC PETERSON, RURY R HOLMAN, PAUL W ARMSTRONG, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):587-P [Abstract]
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857242 Email: dtu@dtu.ox.ac.uk
